Company intelligence / Profile preview

Biovator

Lund, Sweden

Ownership: Private
Employees: ~40
Development stage: Other

Overview

SenzaGen is a Swedish biotechnology company that specializes in next-generation in vitro testing for the assessment of chemical-induced sensitization. Originally founded as Biovator AB, the company developed the GARD (Genomic Allergen Rapid Detection) platform, which utilizes genomic biomarkers and machine learning to provide highly accurate safety assessments for the pharmaceutical, cosmetic, and chemical industries. SenzaGen's technology offers a reliable alternative to animal testing, focusing on skin and respiratory sensitization. The company is headquartered in Lund and is listed on the Nasdaq First North Growth Market.

Therapeutic areas: PulmonologyDermatology
Industry: Molecular Diagnostics

Partnerships

Charles River LaboratoriesEurofins ScientificBurleson Research TechnologiesToxys

Beyond the preview

Go deeper on Biovator.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biovator.

Explore the full profile